TNXP: NDA Filed for TNX-102 SL in Fibromyalgia
On October 16, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it submitted the New Drug Application (NDA) for TNX-102 SL for the...
346 Views
TNXP: Mpox Declared a Public Health Emergency of International Concern by World Health Organization
In August 2024, the World Health Organization (WHO) declared mpox a public health emergency of international concern. The number of cases of mpox...
236 Views
TNXP: High Interest in Tonmya Seen in Initial Findings from Market Opportunity Analysis
On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the first quarter of 2024 and provided a business...
205 Views
TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025
On April 1, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the fourth quarter and full year 2023 and provided a...
279 Views
Time to execute
With the commencement of enrolment for the pivotal Phase III HONOR study of TNX-102 SL in military-related post-traumatic stress disorder (PTSD),...
135 Views